A novel missense variant in HIKESHI: Clinical phenotype, in vitro functional testing, and potential for gene therapy

Abstract A 7‐month‐old boy presented to our clinic with developmental delay, Magnetic Resonance Imaging (MRI) features of delayed myelination and diffusion restriction, and a homozygous variant of uncertain significance (c.4T>G, p.Phe2Val) in HIKESHI , a gene associated with autosomal‐recessive hypomyelinating leukodystrophy 13. We hypothesized that the variant is disease‐causing and aimed to rescue the cellular phenotype with vector‐mediated gene replacement. HIKESHI mediates heat‐induced nuclear accumulation of heat‐shock proteins, including HSP70, to protect cells from stress. We generated skin fibroblasts from the proband and proband's mother (heterozygous) to compare protein expression and subcellular localization of HSP70 under heat stress conditions, and the effect of vector‐mediated overexpression of HIKESHI in the proband's cells under the same heat stress conditions. Western blot analysis revealed absent HIKESHI protein from proband fibroblasts, contrasted with ample expression in parental cells. Under heat stress conditions, while the mother's cells displayed appropriate nuclear localization of HSP70, the proband's cells displayed impaired nuclear translocalization. When patient fibroblasts were provided exogenous HIKESHI, the transfected proband's cells showed restored heat‐induced nuclear translocalization of HSP70 under conditions of heat stress. These functional data establish that the patient's variant is a pathogenic loss‐of‐function mutation, thus confirming a diagnosis of hypomyelinating leukodystrophy 13 and that vector‐mediated gene replacement may be an effective treatment approach for patients with this disorder.